Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Current Assets (2020 - 2025)

Historic Current Assets for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to $237.6 million.

  • GeneDx Holdings' Current Assets rose 2772.59% to $237.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.6 million, marking a year-over-year increase of 2772.59%. This contributed to the annual value of $198.0 million for FY2024, which is 857.14% up from last year.
  • Latest data reveals that GeneDx Holdings reported Current Assets of $237.6 million as of Q3 2025, which was up 2772.59% from $204.8 million recorded in Q2 2025.
  • GeneDx Holdings' Current Assets' 5-year high stood at $538.5 million during Q3 2021, with a 5-year trough of $99.0 million in Q2 2021.
  • In the last 5 years, GeneDx Holdings' Current Assets had a median value of $212.6 million in 2022 and averaged $253.2 million.
  • Its Current Assets has fluctuated over the past 5 years, first skyrocketed by 3664786.97% in 2021, then tumbled by 5602.84% in 2022.
  • GeneDx Holdings' Current Assets (Quarter) stood at $483.5 million in 2021, then plummeted by 56.03% to $212.6 million in 2022, then fell by 14.24% to $182.3 million in 2023, then increased by 8.57% to $198.0 million in 2024, then grew by 20.01% to $237.6 million in 2025.
  • Its Current Assets was $237.6 million in Q3 2025, compared to $204.8 million in Q2 2025 and $225.8 million in Q1 2025.